Keith R Abrams
Overview
Explore the profile of Keith R Abrams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
5370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Owen R, van Oppen J, Lyons J, Akbari A, Davies G, Torabi F, et al.
Euro Surveill
. 2024 Dec;
29(50).
PMID: 39668763
BackgroundThe COVID-19 pandemic resulted in increased mortality directly and indirectly associated with COVID-19.AimTo assess the impact of the COVID-19 pandemic on all-cause and disease-specific mortality and explore potential health inequalities...
2.
Daigl M, Abogunrin S, Castro F, McGough S, Sturrup R, Boersma C, et al.
J Comp Eff Res
. 2024 Oct;
13(12):e240101.
PMID: 39392412
Comparative effectiveness research (CER) is essential for making informed decisions about drug access. It provides insights into the effectiveness and safety of new drugs compared with existing treatments, thereby guiding...
3.
Schiava M, McDermott M, Broomfield J, Abrams K, Mayhew A, McDonald C, et al.
Neurology
. 2024 May;
102(10):e209206.
PMID: 38710006
Background And Objectives: Clinical trials in Duchenne muscular dystrophy (DMD) require 3-6 months of stable glucocorticoids, and the primary outcome is explored at 48-52 weeks. The factors that influence the...
4.
Fagbamigbe A, Agrawal U, Azcoaga-Lorenzo A, MacKerron B, Ozyigit E, Alexander D, et al.
PLoS One
. 2023 Nov;
18(11):e0294666.
PMID: 38019832
There is still limited understanding of how chronic conditions co-occur in patients with multimorbidity and what are the consequences for patients and the health care system. Most reported clusters of...
5.
Broomfield J, Abrams K, Freeman S, Latimer N, Rutherford M, Crowther M
Stat Med
. 2023 Nov;
43(1):184-200.
PMID: 37932874
Multi-state survival models are used to represent the natural history of a disease, forming the basis of a health technology assessment comparing a novel treatment to current practice. Constructing such...
6.
Umemneku-Chikere C, Wheaton L, Poad H, Ray D, Andrade I, Khan S, et al.
J Clin Epidemiol
. 2023 Nov;
164():96-103.
PMID: 37918640
Objectives: We aimed to develop a network meta-analytic model for the evaluation of treatment effectiveness within predictive biomarker subgroups, by combining evidence from individual participant data (IPD) from digital sources...
7.
Turner A, Sammon C, Latimer N, Adamson B, Beal B, Subbiah V, et al.
Pharmacoeconomics
. 2023 Oct;
42(2):165-176.
PMID: 37891433
Internal validity is often the primary concern for health technology assessment agencies when assessing comparative effectiveness evidence. However, the increasing use of real-world data from countries other than a health...
8.
Lyons J, Akbari A, Abrams K, Azcoaga Lorenzo A, Ba Dhafari T, Chess J, et al.
Lancet Reg Health Eur
. 2023 Jul;
32:100687.
PMID: 37520147
Background: Understanding and quantifying the differences in disease development in different socioeconomic groups of people across the lifespan is important for planning healthcare and preventive services. The study aimed to...
9.
Owen R, Lyons J, Akbari A, Guthrie B, Agrawal U, Alexander D, et al.
Lancet Public Health
. 2023 Jul;
8(7):e535-e545.
PMID: 37393092
Background: To inform targeted public health strategies, it is crucial to understand how coexisting diseases develop over time and their associated impacts on patient outcomes and health-care resources. This study...
10.
Shupo F, Abrams K, Ademi Z, Wayi-Wayi G, Zibelnik N, Kirchmann M, et al.
Pharmacoecon Open
. 2023 Jun;
7(5):777-792.
PMID: 37306929
Objectives: This paper presents an Australian model that formed part of the health technology assessment for public investment in siltuximab for the rare condition of idiopathic Multicentric Castleman Disease (iMCD)...